Sterling Pharma buys contract services provider NewChem

Sterling Pharma Solutions has concluded the acquisition of UK-based contract services provider NewChem Technologies for an undisclosed sum.

NewChem has expertise in organic chemistry and serves customers in sectors including pharmaceuticals, biotechnology, diagnostics, veterinary science and chemicals.

Established in 2002 as a spin-off from Newcastle University School of Chemistry, NewChem enhances Sterling’s capabilities in addressing complex process chemistry challenges, synthesising molecules and assisting customers in determining their most viable path for development and scaling up.

Sterling has acquired all the assets and employees of NewChem.

The laboratory facilities of NewChem are situated within Newcastle upon Tyne’s Biosphere.

The site will collaborate closely with Sterling’s facility in Cary, North Carolina, US. This serves as an early-phase development centre.

NewChem founders Dr Bob Tyson and Professor Bernard Golding will retain their positions as site head and science director.

Sterling CEO Kevin Cook stated: “The expertise and experience within the well-respected and talented NewChem team will provide the business with additional capacity to solve complex chemistry challenges.

“NewChem’s connections with academia are closely aligned with Sterling’s technology and innovation programme, which sees us work with a number of leading global academic institutions to bring the latest technologies and innovations to our customers.”

Sterling’s global presence encompasses its UK headquarters in Cramlington near Newcastle, its manufacturing facility, a newly GMP-licensed bioconjugation centre in Deeside, a 111-acre site in Ringaskiddy, Ireland, and two US locations, in Cary and in Germantown, Wisconsin.